title: Implementing therapeutic goals in maintenance treatment of psoriasis with biologics: adalimumab can be more cost-effective than infliximab or ustekinumab in real life.
authors.affiliation: Department of Dermatology, Hospital de la Santa Creu i Sant Pau,, Universitat Autònoma de Barcelona, Sant Antoni Maria Claret 167, 08025 Barcelona, Spain.
authors.forename: Lluís
authors.initials: L
authors.lastname: Puig
authors.affiliation: Department of Dermatology, Hospital de la Santa Creu i Sant Pau,, Universitat Autònoma de Barcelona, Sant Antoni Maria Claret 167, 08025 Barcelona, Spain.
authors.forename: Caridad-Elena
authors.initials: CE
authors.lastname: Morales-Múnera
mesh_terms: D000068879:Adalimumab / Q000191:economics* / Q000627:therapeutic use*; D001688:Biological Products / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D006801:Humans; D000069285:Infliximab / Q000191:economics* / Q000627:therapeutic use*; D060046:Maintenance Chemotherapy; D011565:Psoriasis / Q000188:drug therapy*; D012189:Retrospective Studies; D000069549:Ustekinumab / Q000191:economics* / Q000627:therapeutic use*
chemical_list: D001688:Biological Products; D000069285:Infliximab; D000069549:Ustekinumab; D000068879:Adalimumab